Novo Nordisk files a supplemental NDA seeking approval for a higher-dose version of weight-loss drug Wegovy (semaglutide).
A law journal article, discussed in Regulatory Review, proposes a framework courts could use to consider state challenges to federal preemption of drug regulation that conflict with FDA actions.
Novo Nordisk files a supplemental NDA seeking approval for a higher-dose version of weight-loss drug Wegovy (semaglutide).
A law journal article, discussed in Regulatory Review, proposes a framework courts could use to consider state challenges to federal preemption of drug regulation that conflict with FDA actions.
The Department of Justice says a Massachusetts federal judge sentenced three former Magellan Diagnostics executives for hiding a malfunction in the company’s Lead Care medical devices.
FDA approves AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy as a perioperative treatment for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
